Ignite Creation Date:
2024-05-06 @ 12:01 AM
Last Modification Date:
2024-10-26 @ 10:43 AM
Study NCT ID:
NCT01473095
Status:
COMPLETED
Last Update Posted:
2017-10-23
First Post:
2011-11-10
Brief Title:
Phase 1 Dose Escalation Study of ARQ 092 in Adult Subjects With Advanced Solid Tumors and Recurrent Malignant Lymphoma
Sponsor:
ArQule Inc a subsidiary of Merck Sharp Dohme LLC a subsidiary of Merck Co Inc Rahway NJ USA
Organization:
ArQule Inc a subsidiary of Merck Sharp Dohme LLC a subsidiary of Merck Co Inc Rahway NJ USA
Conditions & Keywords Data
Conditions:
| Name |
|---|
| Tumor |
| Solid Tumor |
| Malignant Lymphoma |
Keywords:
| Name | View |
|---|---|
| PIK3CA H1047R mutation | View |
| AKT | View |
| ARQ 092 | View |
| Targeted therapy | View |
| Molecular therapy | View |
| Biomarker | View |
| Phase 1 | View |
| Phase I | View |
| Endometrial cancer | View |
| Lymphoma | View |
| AKT pathway | View |
| AKT signaling | View |
| AKT inhibitor | View |
| AKT pan inhibitor | View |
| AKT1 | View |
| AKT2 | View |
| AKT3 | View |
| AKT1 mutation | View |
| AKT1-E17K | View |
| AKT1-E17K mutation | View |
| AKT 2 inhibitor | View |
| AKT 3 inhibitor | View |
| AKT 3 amplification | View |
| PI3K AKT mTOR signalling pathway | View |
| mTOR inhibitor | View |
| PI3K inhibitor | View |
| Clinical oncology | View |
| Tumor | View |
| Tumour | View |